You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for New Drug Application (NDA): 020316


✉ Email this page to a colleague

« Back to Dashboard


NDA 020316 describes OXILAN-350, which is a drug marketed by Guerbet and is included in one NDA. Additional details are available on the OXILAN-350 profile page.

The generic ingredient in OXILAN-350 is ioxilan. There is one drug master file entry for this compound. Additional details are available on the ioxilan profile page.
Summary for 020316
Tradename:OXILAN-350
Applicant:Guerbet
Ingredient:ioxilan
Patents:0

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength62%
Approval Date:Dec 21, 1995TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength73%
Approval Date:Dec 21, 1995TE:RLD:No

Expired US Patents for NDA 020316

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Guerbet OXILAN-300 ioxilan INJECTABLE;INJECTION 020316-001 Dec 21, 1995 ⤷  Sign Up ⤷  Sign Up
Guerbet OXILAN-350 ioxilan INJECTABLE;INJECTION 020316-002 Dec 21, 1995 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.